

Patient

Name **Jane Jones**
Date of Birth (Age) **11/27/1940 (83 yrs)**
Assigned Sex at Birth **Female**
Diagnosis **Non-Small Cell Lung Carcinoma**
Medical Record # **ID400231**
Internal Patient ID **10000090**

Sample

Specimen Type **Blood**
Collection Date **09/18/2024**
Receipt Date **09/20/2024**
Accession ID **V010900AA001-1**
Report Date **02/28/2025**
Test Number **2**

Physician

Ordering Physician **John Smith**
Medical Facility **BillionToOne Inc**
Address **1035 O'Brien Drive Menlo Park, California 94025**
Phone **(833) 537-1819**
Fax **(833) 874-0918**

Northstar Select Results

2

informative genomic alterations identified

Summary of Informative Genomic Alterations

Detected Genomic Findings [§]	Associated FDA-Approved and/or Guideline Recommended Therapies			Clinical Trials [§]	VAF / Copy number
	✓ Approved in indication	⊙ Approved in other indication	✗ Associated with resistance		
EGFR L747_P753delinsS	<ul style="list-style-type: none">afatinibafatinib/cetuximab^Gamivantamab^Gbevacizumab/erlotinib^Gdacomitiniberlotiniberlotinib/ramucirumabgefitinibosimertinib			10	0.15%
TP53 F338Sfs*4				0	0.17%

^G Treatment listed is based upon recommendation from professional guidelines only. Please consult professional guidelines and FDA indications for complete details.

[§] For additional information, please see the **Variant Details** and **Clinical Trials** section of the report.

Microsatellite Instability-High

Microsatellite Instability-High (MSI-H) is reported here as detected/not detected based upon mutation analysis at curated genomewide MSI sites and subsequent bioinformatic algorithm calculation.

Not Detected Detected

Summary of Guideline-Recommended Genes Evaluated

The following guideline-recommended genes for Non-Small Cell Lung Carcinoma were evaluated. Variants not listed in the tables above are considered 'Not Detected'. For a complete list of genes tested, refer to the Methods section of the report.

ALK

BRAF

EGFR

ERBB2 (HER2)

KRAS

MET

NTRK

RET

ROS1

Patient Name	Jane Jones	Date of Birth (Age)	11/27/1940 (83 yrs)	Assigned Sex at Birth	Female
Diagnosis	Non-Small Cell Lung Carcinoma	Internal Patient ID	10000090	Report Date	02/28/2025

Genes with copy number signal indicating potential for aneuploidy

Changes in copy number due to biological factors including aneuploidy can confound the accurate detection of clinically informative copy number alterations (CNAs). The following genes have deviations in copy number signal but are not called for copy number amplification/loss due to observed patterns of copy number signal (i.e. aneuploidy) within the chromosomal arm and/or other chromosomal arms of the sample.

Copy number signal indicating potential aneuploidy was not detected in any gene.

Variants of Unknown Significance (VUS)

The clinical relevance of these variants is currently unknown. Therefore, the functional impact of targeting these variants cannot be determined at this time.

No Variants of Unknown Significance detected.

Clinical Trial Availability

Clinical trial matches are displayed based upon somatic variant detection and patient demographic and diagnostic information provided on the test requisition form. Trials are matched within 500 miles of the ordering provider's location. This list is neither comprehensive nor a guarantee of eligibility, as many other requirements must be met prior to enrollment.

For further details on eligibility, please visit www.clinicaltrials.gov and enter the NCT#.

Phase 3 NCT06396065	A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment EGFR L747_P753delinsS	Bethesda, Maryland (20817) American Oncology Partners
Phase 3 NCT04181060	Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) EGFR L747_P753delinsS	Hanover, Pennsylvania (17331) WellSpan Medical Oncology and Hematology
Phase 2 NCT05498428	A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer EGFR L747_P753delinsS	District of Columbia, District of Columbia (20016) Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital
Phase 2 NCT04410796	A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients With Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib EGFR L747_P753delinsS	Basking Ridge, New Jersey (07920) Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Phase 2 NCT03786692	TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked EGFR L747_P753delinsS	Philadelphia, Pennsylvania (19111) Fox Chase Cancer Center
Phase 2 NCT03586453	A Phase II Study of Osimertinib With On-study and Post-progression Biopsy in the First Line Treatment of EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer EGFR L747_P753delinsS	Boston, Massachusetts (02215) Beth Israel Deaconess Medical Center
Phase 1/Phase 2 NCT05908734	A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer EGFR L747_P753delinsS	Fairfax, Virginia (22031) Virginia Cancer Specialists

Patient Name	Jane Jones	Date of Birth (Age)	11/27/1940 (83 yrs)	Assigned Sex at Birth	Female
Diagnosis	Non-Small Cell Lung Carcinoma	Internal Patient ID	10000090	Report Date	02/28/2025

Phase 1/Phase 2 NCT05519293	A Phase I/IIa, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-tumor Activity of H002 in Patients With Active EGFR Mutation Locally Advanced or Metastatic NSCLC	Fairfax, Virginia (22031) NEXT Virginia
---------------------------------------	---	---

EGFR L747_P753delinsS

Phase 1/Phase 2 NCT05109442	A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination With Atezolizumab in Patients With Selected Advanced/ Metastatic EGFR-expressing Cancers	Baltimore, Maryland (21287) Johns Hopkins University
---------------------------------------	--	--

EGFR L747_P753delinsS

Phase 1 NCT04077463	An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer	Fairfax, Virginia (22031) Virginia Cancer Specialists
-------------------------------	---	---

EGFR L747_P753delinsS

Variant Details

EGFR

EGFR activating mutations or amplification may predict sensitivity to Egfr-targeted therapies, including inhibitors of multiple ErbB family members, and several have received agency approval in some tumor types [1, 2, 3]. The Egfr TKIs erlotinib, afatinib, gefitinib, osimertinib, and dacomitinib, as well as the combination of amivantamab plus lazertinib, have been approved by the FDA for the treatment of non-small cell lung cancer (NSCLC) with exon 19 deletion or L858R EGFR mutations; osimertinib has additionally been approved for the treatment of NSCLC with EGFR T790M [4, 5, 6, 7, 8, 9, 10, 1, 11]. Afatinib has additionally been FDA-approved for the treatment of NSCLC with S768I, L861Q, and/or G719X mutations [12]. The combination of erlotinib and ramucirumab as well as osimertinib plus platinum-based chemotherapy have been FDA-approved for the treatment of metastatic NSCLC patients with tumors harboring an EGFR exon 19 deletion or the exon 21 L858R mutation [13, 14]. Amivantamab in combination with carboplatin and pemetrexed has been FDA-approved for the treatment of adult patients with locally advanced or metastatic NSCLC harboring EGFR Exon 19 deletions or Exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR TKI [11]. Amivantamab has also been approved by the FDA for NSCLC patients with EGFR exon 20 insertions, whose disease has progressed on or after platinum-based chemotherapy and as frontline therapy in combination with carboplatin and pemetrexed. The accelerated FDA approval of mobocertinib for NSCLC patients with EGFR exon 20 insertions has been withdrawn due to lack of progression-free survival benefit in the confirmatory Phase 3 trial [15]. Although one study has reported the emergence of EGFR L747_P753delinsS in a non-small cell lung cancer patient with disease progression after osimertinib treatment, a separate study has reported response to osimertinib in 4/7 patients with EGFR L747_P753delinsS who acquired EGFR T790M mutation [16, 17].

EGFR L747_P753delinsS

Gene	EGFR
Nucleotide	NM_005228.5: c.2240_2257del
Amino Acid	p.L747_P753delinsS
Exon	19
Biomarker Type	activating

EGFR L747_P753delinsS is an in-frame deletion in exon 19 that occurs in the tyrosine kinase domain of the Egfr protein (UniProt, IGV). This alteration and other exon 19 deletions have been shown to activate Egfr tyrosine kinase activity, result in increased cell growth as compared with wild-type Egfr, and confer sensitivity to Egfr tyrosine kinase inhibitors such as erlotinib, afatinib, dacomitinib, and gefitinib [18, 19, 20, 21, 22, 23]. EGFR L747_P753delinsS has been reported as an uncommon exon 19 indel alteration in NSCLC patients and has been observed to exhibit median progression-free survival of 15-20 months following first-line Egfr TKI therapy, longer than patients with common EGFR exon 19 deletions [17, 24]. Although one study has reported the emergence of EGFR L747_P753delinsS in a non-small cell lung cancer patient with disease progression after osimertinib treatment, a separate study has reported response to osimertinib in 4/7 patients with EGFR L747_P753delinsS who acquired EGFR T790M mutation [16, 17]. A study has reported reduced sensitivity to osimertinib as compared with erlotinib and gefitinib in NSCLC preclinical models with EGFR L747_P753delinsS, however, tumor growth was still reduced significantly with osimertinib. In a cohort of NSCLC patients with uncommon EGFR exon 19 delins mutations, including EGFR L747_P753delinsS, reduced progression-free and overall survival was observed with first-line Egfr therapies as compared with third-line therapies [25].

Patient Name **Jane Jones**
 Diagnosis **Non-Small Cell Lung Carcinoma**

Date of Birth (Age) **11/27/1940 (83 yrs)**
 Internal Patient ID **10000090**

Assigned Sex at Birth **Female**
 Report Date **02/28/2025**

TP53

TP53 is a tumor suppressor that encodes the p53 protein; alterations in TP53 may result in a loss of p53 function, yet an increase in the expression and stability of the mutant p53 protein in the nucleus, sometimes leading to oncogenic effects, including genomic instability and excessive cell proliferation [26, 27, 28, 29, 30, 31]. At present, there are no approved therapies targeting TP53 alterations, despite their high prevalence in cancer. Therapeutic approaches under investigation include gene therapy for TP53 and (dendritic cell-based) TP53 vaccines [32, 33, 34]. Tumors with TP53 mutations may be sensitive to the Wee1 inhibitor adavosertib (MK-1775), and clinical trials are currently underway for patients with solid tumors and hematologic malignancies [35, 36]. Aurora kinase A inhibitors are another therapeutic approach under investigation for TP53 -mutated cancers [37, 38, 39, 40, 41].

TP53 F338Sfs*4

Gene **TP53**
 Nucleotide **NM_000546.6: c.1013_1022del**
 Amino Acid **p.F338Sfs*4**
 Exon **10**
 Biomarker Type **inactivating**

The frameshift alteration reported here is expected to effectively truncate the p53 protein within the tetramerization domain; this truncation is expected to result in the loss of a portion of the tetramerization domain and the entire C-terminal regulatory domain [42]. The tetramerization domain is thought to be critical to normal p53 function [43, 29]. In addition, the C-terminal regulatory domain has been shown to be required for DNA binding and transcriptional activation by p53 [44]. Furthermore, this alteration is likely to elicit nonsense-mediated decay [45, 46, 47, 48]. Therefore, this alteration is predicted to be inactivating.

Patient Name **Jane Jones**
 Diagnosis **Non-Small Cell Lung Carcinoma**

Date of Birth (Age) **11/27/1940 (83 yrs)**
 Internal Patient ID **10000090**

Assigned Sex at Birth **Female**
 Report Date **02/28/2025**

Interpretation

Genomic alterations (SNVs/indels/fusions) were detected in the cell-free DNA (cfDNA) isolated from the patient's blood specimen. The variant frequency of the mutations, reported as variant allele fraction (VAF), is calculated and reported for detected SNVs and indels. These alterations may be informative to cancer treatment response and/or clinical trial eligibility. While somatic actionability is of primary concern when determining report inclusion, some variants may be included without matched actionable outcomes. These variants may be critical to carcinogenesis in the patient's tumor.

Methods and Limitations

Northstar Select® is a next generation sequencing (NGS)-based in vitro diagnostic test for detection of substitutions (SNVs), small insertion and deletion alterations (indels), selected genes' copy number alterations (CNAs, including amplifications and deletions) and selected gene-rearrangements in a total of 84 genes (Table 1), as well as microsatellite instability-high (MSI-H) status. Cell-free DNA (cfDNA) is extracted from plasma, and the targeted regions, encompassing >250kb, are amplified and sequenced. The sensitivity of the test is 100% (95% CI: [99.84%,100.00%]) for SNVs and indels for variant allele fraction (VAF) ≥0.5% and fusions examined in the assay analytical validation, and 100% (95% CI: [76.84%,100.00%]) for CNAs. The limit of detection for the assay is 0.15% VAF for SNVs and indels. However, key actionable variants may be reported at lower VAFs where technically feasible. The overall base-wise specificity of the Northstar Select® test is >99.99%, leading to high confidence in true positive reporting for variants with VAF >0.2%, despite the expansive genomic loci targeted and assayed. For CNAs, the LOD for gene amplifications is 2.11 copies and for loss is 1.8 copies. CNA LOD is subject to aneuploidy noise, with less aneuploid samples having a superior LOD. The copy number displayed on the report represents gene copies in liquid. Thresholds have been set to report homozygous loss for deletions, focal amplifications, or high-level amplifications (e.g. >6 copies estimated in the solid tumor). Observed increased or decreased copy number may not be called as CNAs despite potentially reflecting a characteristic (ie aneuploidy) of the tumor biology. These genes with copy number signal indicating potential for aneuploidy are listed in the corresponding section of the report (except for the AR gene located on the X-chromosome, which will not be subject to this additional analysis). MSI score is calculated using a count of somatic indel mutations in targeted microsatellite sites; based upon meeting threshold, MSI-H status is reported when detected. The sensitivity of the MSI component is 100% (95% CI: [97.72%,100.00%]) for MSI-H at a tumor fraction of ≥0.5%, and the limit of detection of the assay for MSI-H is 0.07-0.4% tumor fraction. An MSI-Indeterminate result is an inconclusive result as it does not suggest the presence or absence of MSI-H in the patient. For certain cfDNA sample or variant characteristics, such as low cfDNA input or high level of cancer-associated chromosomal copy abnormality, the analytical sensitivity may be reduced.

Variants detected in the cfDNA are aligned to the hg19 reference genome. Informative genomic alterations are potentially actionable or biologically relevant variants based on evidence from medical and scientific literature. Variants of unknown significance (VUS) are genomic alterations that do not have sufficient evidence to determine biological/clinical significance. Variants classified as benign, likely benign, and variants likely originating from a pseudogene are not reported.

Genomic profiling of tumors can detect alterations not associated with the tumor itself but due to clonal hematopoiesis (CH). This assay cannot differentiate whether variants detected in the cfDNA are derived from a patient's solid tumor or clonal blood cells. Variants indicating CH, which are found most commonly in specific genes, may be detected, especially in older individuals or previously systemically treated patients (e.g., chemotherapy), and may impact targeted treatment efficacy. Clinical guidelines state that caution is warranted in interpreting ctDNA-only somatic alterations in genes indicated for PARP inhibitors and actionable tumor suppressor genes [49]. In alignment with guideline recommendations, detected alterations in these genes and other genes that are most CH-prone are flagged: *ATM*, *BRCA1*, *BRCA2*, *BRIP1*, *CDK12*, *CHEK2*, *FANCA*, *JAK2*, *MLH1*, *NF1*, *PALB2*, *PTEN*, *RAD51C*, *RAD51D*, and *SF3B1* [49, 50, 51, 52]. Buffy coat enriched for white blood cells is currently stored by the laboratory in case further testing is necessary. This report should not be used in place of a dedicated hematological evaluation. Any interpretations should take into consideration the patient's clinical context.

Reported treatments and trials should be comprehensively evaluated by the medical provider, as inclusion in the report is neither a guarantee of treatment/trial match, nor intended to be fully comprehensive. Treatments and trials are reported based upon the information provided at the time of test requisition, including diagnosis, sex, age, and location, and may not account for all elements of the patient's medical history. Certain treatments may have specifications surrounding other clinical factors, such as HR/HER2-status or germline mutation origin. The ordering provider should consult official FDA-approval information for full approval specifications, as well as professional guidelines for complete recommendations. Inclusion in Northstar Select® does not guarantee that reported treatments or trials will have an impact on clinical outcome.

This assay is validated for the detection of somatic variants, but was not developed to distinguish germline variants, which may predispose the patient to certain types of cancer, from detected somatic variants. Incidental findings will be interpreted and reported in the context of somatic disease. For variants with a VAF reported at >40%, separate germline testing may be recommended to identify and characterize such variants that may have hereditary implications.

Table 1: Genes on the Northstar Select® panel

Northstar Select® reports single nucleotide variants, insertion and deletion variants (indels), and splice site mutations for clinically relevant exons in 82 genes, copy number amplifications in 19 genes, and copy number loss in 5 genes, and fusion events in 9 genes, as detailed in the table below. This assay was designed for blood-based molecular profiling of solid tumors; while indicated for use, gene coverage may not meet guideline recommendations for certain cancer types such as sarcomas and lymphomas.

AKT1, *AKT2*, *ALK*[^], *APC*, *AR*⁺, *ARAF*, *ARID1A*, *ATM*⁻, *BRAF*^{F+}, *BRCA1*⁻, *BRCA2*⁻, *BRIP1*, *CCND1*, *CCND2*, *CCNE1*⁺, *CD274*⁺, *CDH1*, *CDK12*, *CDK4*⁺, *CDK6*⁺, *CDKN2A*⁻, *CDKN2B*, *CHEK2*, *CTNNB1*, *DDR2*, *EGFR*⁺, *ERBB2*⁺, *ESR1*⁺, *EZH2*, *FANCA*, *FBXW7*, *FGFR1*⁺, *FGFR2*⁺, *FGFR3*^Δ, *FGFR4*, *GATA3*, *GNA11*, *GNAQ*, *GNAS*, *HRAS*, *IDH1*, *IDH2*, *JAK2*, *JAK3*, *KIT*⁺, *KRAS*⁺, *MAP2K1*, *MAP2K2*, *MET*⁺, *MLH1*, *MPL*, *MSH2*, *MSH6*, *MTOR*, *MYC*⁺, *NF1*, *NOTCH1*, *NPM1*, *NRAS*, *NTRK1*^Δ, *NTRK2*^Δ, *NTRK3*^Δ, *PALB2*, *PDGFRA*⁺, *PIK3CA*⁺, *PMS2*, *PTEN*⁻, *PTPN11*, *RAD51C*, *RAD51D*, *RAF1*⁺, *RB1*, *RET*^Δ, *RHOA*, *RIT1*, *ROS1*^Δ, *SF3B1*, *SMAD4*, *SMO*, *STK11*, *TERT*, *TP53*, *TSC1*, *VHL*

[^] Northstar Select® also reports fusion events for this gene

^Δ Northstar Select® reports only fusion events for these genes, no SNVs and indels will be reported; *NTRK3* is limited to *NTRK3-ETV6* fusions only

⁺ Northstar Select® also reports copy number amplifications of this gene

⁻ Northstar Select® also reports copy number deletions of this gene

Patient Name	Jane Jones	Date of Birth (Age)	11/27/1940 (83 yrs)	Assigned Sex at Birth	Female
Diagnosis	Non-Small Cell Lung Carcinoma	Internal Patient ID	10000090	Report Date	02/28/2025

References

1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*. 2009 Sep 03;361(10):947-57. Epub 2009 Aug 19. PMID:19692680.
2. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. *N Engl J Med*. 2009 Sep 03;361(10):958-967. Epub 2009 Aug 19. PMID:19692684.
3. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. *N Engl J Med*. 2005 Jul 14;353(2):133-44. PMID:16014883.
4. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. *N Engl J Med*. 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18. PMID:29151359.
5. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2017 Nov;18(11):1454-1466. Epub 2017 Sep 25. PMID:28958502.
6. Mok TS, Cheng Y, Zhou X, et al. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. *J Clin Oncol*. 2018 Aug 01;36(22):2244-2250. Epub 2018 Jun 4. PMID:29864379.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. *The New England journal of medicine*. N Engl J Med 2005 Jul 14;353(2):123-32. PMID:16014882.
8. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*. 2012 Mar;13(3):239-246. Epub 2012 Jan 26. PMID:22285168.
9. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol*. 2013 Sep 20;31(27):3327-3334. Epub 2013 Jul 1. PMID:23816960.
10. Douillard JY, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. *Br J Cancer*. 2014 Jan 07;110(1):55-62. Epub 2013 Nov 21. PMID:24263064.
11. Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. *Ann Oncol*. 2024 Jan;35(1):77-90. Epub 2023 Oct 23. PMID:37879444.
12. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. *Lancet Oncol*. 2015 Jul;16(7):830-8. Epub 2015 Jun 4. PMID:26051236.
13. Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2019 Dec;20(12):1655-1669. Epub 2019 Oct 4. PMID:31591063.
14. Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. *The New England journal of medicine*. N Engl J Med 2023 Nov 23;389(21):1935-1948. PMID:37937763.
15. Riely GJ, Neal JW, Camidge DR, et al. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. *Cancer Discov*. 2021 Jul;11(7):1688-1699. Epub 2021 Feb 25. PMID:33632775.
16. Bar J, Peled N, Schokrpur S, et al. UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-Line Setting (UNICORN). *J Thorac Oncol*. 2023 Feb;18(2):169-180. Epub 2022 Oct 25. PMID:36307041.
17. Peng X, Long X, Liu L, et al. Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer. *Eur J Cancer*. 2020 Dec;141:199-208. Epub 2020 Nov 7. PMID:33171317.
18. Ng PK, Li J, Jeong KJ, et al. Systematic Functional Annotation of Somatic Mutations in Cancer. *Cancer Cell*. 2018 Mar 12;33(3):450-462.e10. PMID:29533785.
19. Truini A, Starrett JH, Stewart T, et al. The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. *Clin Cancer Res*. 2019 Nov 01;25(21):6382-6391. Epub 2019 Jun 10. PMID:31182434.
20. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med*. 2004 May 20;350(21):2129-2139. Epub 2004 Apr 29. PMID:15118073.
21. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science*. 2004 Jun 04;304(5676):1497-1500. Epub 2004 Apr 29. PMID:15118125.
22. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A*. 2004 Sep 07;101(36):13306-11. Epub 2004 Aug 25. PMID:15329413.
23. Kancha RK, von Bubnoff N, Peschel C, Duyster J. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. *Clin Cancer Res*. 2009 Jan 15;15(2):460-7. PMID:19147750.
24. Chen Y, Xu J, Zhang L, et al. A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma. *Transl Lung Cancer Res*. 2022 Feb;11(2):238-249. PMID:35280318.
25. Lu Z, Yi Y, Wang L, et al. Non-small cell lung cancer cells with uncommon EGFR exon 19delins variants respond poorly to third-generation EGFR inhibitors. *Transl Oncol*. 2024 Jan;39:101834. Epub 2023 Nov 24. PMID:38006760.
26. Levine AJ. p53, the cellular gatekeeper for growth and division. *Cell*. 1997 Feb 07;88(3):323-331. PMID:9039259.
27. Wang YC, Lin RK, Tan YH, Chen JT, Chen CY, Wang YC. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. *J Clin Oncol*. 2005 Jan 01;23(1):154-64. PMID:15625370.
28. Koga T, Hashimoto S, Sugio K, et al. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation. *Int J Cancer*. 2001 Jul 20;95(4):232-9. PMID:11400116.
29. Kato S, Han SY, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. *Proc Natl Acad Sci U S A*. 2003 Jul 08;100(14):8424-9. Epub 2003 Jun 25. PMID:12826609.
30. Houben R, Hesbacher S, Schmid CP, et al. High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. *PLoS One*. 2011;6(7):e22096. Epub 2011 Jul 8. PMID:21760960.
31. Olivier M, Petitjean A, Marcel V, et al. Recent advances in p53 research: an interdisciplinary perspective. *Cancer Gene Ther*. 2009 Jan;16(1):1-12. Epub 2008 Sep 19. PMID:18802452.
32. Schuler PJ, Harasymczuk M, Visus C, et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. *Clin Cancer Res*. 2014 May 01;20(9):2433-44. Epub 2014 Feb 28. PMID:24583792.
33. Vermeij R, Leffers N, van der Burg SH, Melief CJ, Daemen T, Nijman HW. Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies. *J Biomed Biotechnol*. 2011;2011:702146. Epub 2011 Mar 15. PMID:21541192.
34. Saito H, Ando S, Morishita N, et al. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma. *Anticancer research*. Anticancer Res 2014 Jul;34(7):3365-70. PMID:24982341.
35. Hirai H, Arai T, Okada M, et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. *Cancer biology & therapy*. Cancer Biol Ther 2010 Apr 1;9(7):514-22. PMID:20107315.

Patient Name	Jane Jones	Date of Birth (Age)	11/27/1940 (83 yrs)	Assigned Sex at Birth	Female
Diagnosis	Non-Small Cell Lung Carcinoma	Internal Patient ID	10000090	Report Date	02/28/2025

36. Bridges KA, Hirai H, Buser CA, et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. *Clin Cancer Res*. 2011 Sep 01;17(17):5638-5648. Epub 2011 Jul 28. PMID:21799033.
37. Vilgelm AE, Pawlikowski JS, Liu Y, et al. Mdm2 and aurora kinase inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. *Cancer Res*. 2015 Jan 01;75(1):181-93. Epub 2014 Nov 14. PMID:25398437.
38. Li Z, Sun Y, Chen X, et al. p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma. *Mol Cancer Res*. 2015 Mar;13(3):584-91. Epub 2014 Dec 15. PMID:25512615.
39. Katayama H, Sen S. Functional significance of Aurora kinase A regulatory interactions with p53-ERα complex in human breast cancer cells. *Horm Cancer*. 2011 Apr;2(2):117-124. PMID:21761334.
40. Tentler JJ, Ionkina AA, Tan AC, et al. p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. *Mol Cancer Ther*. 2015 May;14(5):1117-29. Epub 2015 Mar 10. PMID:25758253.
41. Kalous O, Conklin D, Desai AJ, et al. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. *Breast cancer research and treatment*. Breast Cancer Res Treat 2013 Oct;141(3):397-408. PMID:24091768.
42. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. *Annual review of biochemistry*. Annu Rev Biochem 2008;77:557-82. PMID:18410249.
43. Kamada R, Nomura T, Anderson CW, Sakaguchi K. Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation. *J Biol Chem*. 2011 Jan 07;286(1):252-8. Epub 2010 Oct 26. PMID:20978130.
44. Kim H, Kim K, Choi J, et al. p53 requires an intact C-terminal domain for DNA binding and transactivation. *J Mol Biol*. 2012 Feb 03;415(5):843-54. Epub 2011 Dec 9. PMID:22178617.
45. Lindeboom RG, Supek F, Lehner B. The rules and impact of nonsense-mediated mRNA decay in human cancers. *Nature genetics*. Nat Genet 2016 Oct;48(10):1112-8. PMID:27618451.
46. Popp MW, Maquat LE. Nonsense-mediated mRNA Decay and Cancer. *Current opinion in genetics & development*. Curr Opin Genet Dev 2018 Feb;48:44-50. PMID:29121514.
47. Nagy E, Maquat LE. A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. *Trends in biochemical sciences*. Trends Biochem Sci 1998 Jun;23(6):198-9. PMID:9644970.
48. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015 May;17(5):405-424. Epub 2015 Mar 5. PMID:25741868.
49. Pascual J, Attard G, Bidard F-C, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. *Ann Oncol*. 2022 Aug; 33(8): 750-768. PMID:35809752.
50. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *N Engl J Med*. 2014 Dec 25; 371(26): 2477-2487. PMID:25426838.
51. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med*. 2014 Dec 25; 371(26): 2488-2498. PMID:25426837.
52. Jensen K, Konnick EQ, Schweizer MT, et al. Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference. *JAMA Oncol*. 2021 Jan 1; 7(1): 107-110. PMID:33151258.

This NGS-based assay was developed and its performance characteristics determined by BillionToOne, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. BillionToOne, Inc. is regulated under CLIA. This test is used for clinical purposes. It should not be regarded as investigational or for research. This test was performed using BillionToOne's patented technology (www.billiontoone.com/patents).

BillionToOne, Inc.
1035 O'Brien Drive
Menlo Park, CA 94025

Laboratory Director **Joseph Michael Anderson, MD**
Lab ID **CLF-90008579**
CLIA ID **05D2275351**

Phone **(833) 537-1819**
Fax **(833) 874-0918**
Email **support@northstaronc.com**



Joseph Michael Anderson, MD
Laboratory Director
California License: A 98379